Cargando…
Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or refract...
Autores principales: | Alegre, Adrian, Vicuña, Isabel, Aguado, Beatriz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256976/ https://www.ncbi.nlm.nih.gov/pubmed/22253550 http://dx.doi.org/10.4137/CMO.S7275 |
Ejemplares similares
-
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012) -
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
por: Dimopoulos, Meletios, et al.
Publicado: (2010) -
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2014) -
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009) -
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea
por: Kim, Hyo Jung, et al.
Publicado: (2015)